Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats

Pengzhou Hang a, b, #, Jing Zhao c, #, Li Sun c, Minghui Li c, Yu Han c, Zhimin Du a, *, Yue Li b, c, *

a Institute of Clinical Pharmacology, The Second Affiliated Hospital (Key Laboratory of Drug Research, Heilongjiang Higher Education Institutions), Harbin Medical University, Harbin, China
b Heilongjiang Academy of Medical Science, Harbin, China
c Department of Cardiology, The First Affiliated Hospital (Key Laboratory of Cardiac Diseases and Heart Failure), Harbin Medical University, Harbin, China

Received: June 14, 2016; Accepted: September 18, 2016

Abstract

The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity. Previous studies have suggested the cardioprotective effect of brain-derived neurotrophic factor (BDNF). We hypothesize that BDNF could protect against Dox-induced cardiotoxicity. Sprague Dawley rats were injected with Dox (2.5 mg/kg, 3 times/week, i.p.), in the presence or absence of recombinant BDNF (0.4 g/kg, i.v.) for 2 weeks. H9c2 cells were treated with Dox (1 lM) and/or BDNF (400 ng/ml) for 24 hrs. Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro. Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration. Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats. Meanwhile, BDNF increased cell viability, inhibited apoptosis and DNA damage of Dox-treated H9c2 cells. Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways. Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor. In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.

Keywords: BDNF ● doxorubicin ● apoptosis ● Akt ● mTOR ● Bad

Introduction

Doxorubicin (Dox) is a widely used chemotherapeutic drug in clinical setting [1]. Despite successful treatment of various malignancies, Dox-induced dose-dependent progressive myocardial damage seriously limits its clinical usage [2]. Doxorubicin-induced cardiotoxicity is characterized by oxidative stress, DNA damage, cardiomyocyte apoptosis and interstitial fibrosis et al. [3–5]. During the past years, many studies were performed to explore the methods for attenuating Dox-induced cardiac dysfunction [6]. Several agents have been uncovered to protect against the cardiotoxicity of Dox such as angiotensin converting enzyme inhibitors (enalapril) [7], β-blockers (metoprolol, carvediol) [8, 9] and resveratrol [10, 11]. Recently, other new measures were developed to mitigate Dox-induced cardiomyopathy [12, 13]. For example, mesenchymal stem cells produced promising cardioprotective effects against Dox-induced damage by paracrine of potent cytokines such as migration inhibitory factor and growth differentiation factor-15 [12]. However, the direct effects of those cytokines/growth factor on Dox-induced cardiomyopathy remain largely unknown.

doi: 10.1111/jcmm.13012
Brain-derived neurotrophic factor (BDNF) is one of the most abundant neurotrophins in the mammalian central nervous system that promotes neuronal survival and differentiation [14]. Growing studies have documented that BDNF plays crucial roles in the cardiovascular system [15–18]. Among them, two recent studies proved that BDNF modulated the contraction of normal heart [16, 17]. Studies by other laboratories and ours demonstrated BDNF could repair injured myocardium by ameliorating endothelial function and inhibiting cardiomyocyte apoptosis [18, 19]. Previous studies also found that BDNF repressed neuroblastoma cells from chemotherapy-induced apoptosis by activating its receptor tropomyosin receptor kinase B (TrkB) [20, 21]. However, whether BDNF could attenuate Dox-induced cardiotoxicity remains unclear.

PI3K/Akt and mitogen-activated protein kinase (MAPK) are two key intracellular signalling transduction pathways, which participate in various important biological activities such as apoptosis and autophagy [22, 23]. Previous studies have illustrated that activation of Akt and downstream signals, for example, mammalian target of rapamycin (mTOR) and Bad and/or inhibition of p38 MAPK are capable of inhibiting Dox-induced cardiac injury [24–26]. Therefore, this study aimed to investigate determine the therapeutic role of BDNF against Dox-induced cardiotoxicity by regulating Akt or MAPK signals to facilitate their safe use in cancer treatment.

Materials and methods

Animals

All animal experiments were approved by the Experimental Animal Ethics Committee of Harbin Medical University and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (Publication, 8th Edition, 2011). Healthy male Sprague Dawley (SD) rats (weight 220 ± 20 g) were provided by Animal Center of the Second Affiliated Hospital of Harbin Medical University, Harbin, China. The rats have free access to standard rat chow and water and 15 rats were randomly divided into three groups: sham, Dox and BDNF treatment group (5 rats in each group). In Dox group, rats were injected with Dox (2.5 mg/kg, 3 times/week, intraperitoneally) for 2 weeks. In BDNF group, rats were injected with Dox (2.5 mg/kg, 3 times/week, intraperitoneally) for 2 weeks. In BDNF group, rats were pre-treated 30 min. before Dox treatment in the presence or absence of Akti (0.5 µM) and recombinant human BDNF (200 and 400 ng/ml) and/or BDNF scavenger TrkB-Fc (4 µg/ml) were pre-treated 30 min. before Dox treatment in the presence or absence of Akti (0.5 µM). The effects of Akti and TrkB-Fc in this concentration have been validated in previous work [19, 28].

Cell culture

H9c2 cells were cultured in DMEM (high glucose; Corning, Manassas, VA, USA) supplemented with 10% foetal bovine serum and 1% penicillin and streptomycin. The cells were maintained under a water-saturated atmosphere of 95% air and 5% CO2 at 37°C. The cells were exposed to Dox at different concentrations range from 0.3, 1 to 3 µM for different time-points (6, 24 or 48 hrs), respectively. Recombinant human BDNF (200 and 400 ng/ml) and/or BDNF scavenger TrkB-Fc (4 µg/ml) were pre-treated 30 min. before Dox treatment in the presence or absence of Akti (0.5 µM). The effects of Akti and TrkB-Fc in this concentration have been validated in previous work [19, 28].

Cell counting kit-8 assay

Cell viability was determined by cell counting kit-8 (CCK-8) kit as described in the manufacturer’s protocol (Dojindo, Kumamoto, Japan). After stimulation as designated, the supernatant was removed and 100 µl of DMEM medium containing 10% FBS was added. Then, the plate was incubated for 2 hrs in the incubator. The optical density values were read at 450 nm using an Infinite M200 microplate reader (Tecan, Salzburg, Austria). For each sample, five parallel experimental wells were used to evaluate the cell viability.

Transmission electron microscopy

Left ventricles were fixed in 2.5% glutaraldehyde and then rinsed in buffer, post-fixed in PBS 1% OsO4 for 2 hrs. Then, they were stained by 1% uranyl acetate, dehydrated in graded ethanol and embedded in epoxy resin. The sections were electron-stained and observed by electron microscope (JEM-1200; JEOL Ltd., Tokyo, Japan).

Haematoxylin and eosin and Masson trichrome staining

Both left and right ventricular samples were embedded in paraffin and cut into 5 µm thick sections. Then, they were stained with haematoxylin and eosin or Masson trichrome for histological and collagen analysis. The interstitial fibrotic areas were calculated by image analysis software (Image-pro plus 6.0; Media Cybernetics LP, Washington, USA). Collagen volume fraction (CVF) was calculated as the ratio of collagen area to total area.

Echocardiography

Cardiac function was measured by Acuson Sequoia 512 Ultrasound System (Siemens Medical Solutions USA, Inc., Mountain View, CA, USA). Left ventricular end systolic volume (LVESV) and left ventricular end diastolic volume (LVEDV) were measured, and left ventricular ejection fraction (LVEF) and fractional shortening (FS) were calculated.

Measurement of superoxide dismutase, malondialdehyde and glutathione levels

The concentrations of three enzymes including superoxide dismutase (SOD), malondialdehyde (MDA) and reduced glutathione (GSH) in both left and right ventricular homogenate were determined using commercial kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
TUNEL assay

*In situ* Cell Death Detection Kit (TUNEL fluorescence FITC kit; Roche, Indianapolis, USA) was used to examine the apoptosis in rat ventricles and H9c2 cells. After washing with PBS for three times, treated samples were fixed by 4% paraformaldehyde for 1 hr, permeabilized in 0.1% Triton x-100 sodium citrate buffer for 2 min. The nuclei were stained with DAPI (1:30; Beyotime, Haimen, China). Fluorescence staining of ventricles was viewed by Olympus BX-60 microscope (Tokyo, Japan) while fluorescence staining of cells was scanned by a laser scanning confocal microscope (FV1000; Olympus, Tokyo, Japan). Five high power fields were randomly selected and analysed. The ratio of TUNEL-positive cells per field was calculated by Olympus Fluoview version 2.0a Viewer software.

Assessment of DNA damage

DNA damage was evaluated according to previous study [29]. After exposure to Dox in the presence or absence of BDNF, H9c2 cells were fixed in 4% paraformaldehyde solution and probed with anti-γH2AX antibody (Ser139, 20E3; Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C followed by fluorescence-labelled secondary antibody.

---

**Fig. 1** Protein expression of brain-derived neurotrophic factor (BDNF) and tropomyosin-related kinase B (TrkB) in Doxorubicin (Dox) and BDNF-treated rat ventricles. **(A and C)** Representative western blot bands and statistical results of BDNF protein expression normalized by GAPDH in left and right ventricles. **(B and D)** Representative western blot bands and statistical results of TrkB protein expression normalized by GAPDH in left and right ventricles. *P < 0.05 versus sham, #P < 0.05 versus Dox, n = 5 each group.
Immunofluorescence images were captured by a fluorescence microscope (Zeiss, Oberkochen, Germany).

**Flow cytometry**

Annexin-V-FLUOS kit (Roche) was used with procedures described in previous studies [30]. Briefly, H9c2 cells (1 × 10^6 cells/ml) were washed twice with cold PBS and resuspended in 500 µl of binding buffer (10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, 2.5 mM CaCl₂). A total of 5 µl of AnnexinV-FITC and 10 µl of 20 µg/ml PI were then added to the cells, which were analysed with a flow cytometer (BD FACSCanto II, BD Biosciences, San Jose, CA, USA). Viable cells were negative for both PI and Annexin V, while apoptotic cells were positive for Annexin V and negative for PI. Late apoptotic dead cells showed both Annexin V and PI positivity. The apoptotic rate was calculated by BD FACSDiva software.

**Western blot**

Total protein was extracted and separated from both ventricles and H9c2 cells for immunoblotting analysis with the procedures described in our previous work [19]. Membranes were incubated with primary antibodies against BDNF (1:500), TrkB (1:1000), p-Akt (1:1000), t-Akt (1:1000), p-mTOR (1:1000), mTOR (1:1000), p-Bad (1:500), Bad (1:1000), p-ERK (1:2000), extracellular regulated protein kinase (ERK; 1:1000), p-p38 (1:1000), p38 (1:1000) or GAPDH (1:1000) overnight at 4°C, followed by incubation with a fluorescence-labelled secondary antibody (LI-COR Biosciences, Lincoln, NE, USA). The images were scanned on the Odyssey CLx Infrared Imaging System (LI-COR Biosciences). Western blot bands were quantified using Odyssey CLx v2.1 software and normalized to GAPDH as an internal control.

**Reagents**

Anti-BDNF and anti-TrkB antibodies were bought from Abclonal (Wuhan, China). Anti-p-Akt (Ser473), anti-t-Akt, anti-p-mTOR, anti-mTOR, anti-p-Bad (Ser136), anti-Bad, anti-p-ERK (Thr202/Tyr204), anti-ERK, anti-p-p38 (Thr180/Tyr182), anti-p38 and anti-γH2AX (Ser139, 20E3) antibodies were provided by Cell Signaling Technology. Anti-GAPDH antibody was obtained from Kangchen Biotech Co Ltd (Shanghai, China). Doxorubicin was provided by Aladdin Industrial Company (Shanghai, China, purity 98%). Recombinant human BDNF and TrkB-Fc were purchased from R&D Systems (Minneapolis, MN, USA). Akt inhibitor (Akti) was provided by Sigma-Aldrich (St. Louis, MO, USA).

**Statistical analysis**

All value were presented as mean ± S.E.M. and analysed by SPSS17.0 software. Student’s t test was performed for two-group comparisons. One-way ANOVA followed by Dunnet’s test was used for multiple-group comparisons. P < 0.05 was considered significant.

**Fig. 2 Morphological alterations of LV myocytes in Dox and BDNF-treated rats.** (A–F) Transmission electron microscope images showed the ultrastructure changes of LV myocytes of sham, Dox and BDNF-treated rats, at magnification 10,000× and 20,000×, respectively, scale bar: 2 µm. (G–I) Representative images of haematoxylin and eosin staining from left ventricles of sham, Dox and BDNF-treated rats, at magnification 400×, scale bar: 50 µm.
Results

Protein expression of BDNF/TrkB axis in Dox and BDNF-treated rat ventricles

Protein expression of BDNF and its receptor TrkB were detected in both left and right ventricles to observe the change in cardiac BDNF/TrkB axis in Dox-treated myocardium and validate the efficiency of BDNF supplement. Figure 1A indicated that protein expression of BDNF was decreased in left ventricles of Dox-treated rats, which was significantly restored after BDNF administration. Meanwhile, protein expression of TrkB was markedly increased by BDNF, although no significance was found between sham and Dox-treated rats (Fig. 1B). Similar results of BDNF and TrkB expression were obtained in right ventricles (Fig. 1C and D). Thus, cardiac BDNF was down-regulated by Dox and was successfully reversed after BDNF injection. Brain-derived neurotrophic factor/TrkB axis was activated in BDNF-treated rat hearts.

Effects of BDNF on morphological changes of ventricular myocytes in Dox-treated rats

Transmission electron microscopy and haematoxylin and eosin staining were employed to examine the ultrastructural and histological changes of LV myocytes in Dox and BDNF-treated rats. As shown in Figure 2A and D, a clear regular structure was observed in the cardiac muscle fibres of sham rats at different magnifications. However, disorganized myofibres and swollen mitochondria were shown in Dox-treated cardiomyocytes (Fig. 2B and E), which was markedly improved by BDNF (Fig. 2C and F). Similarly, haematoxylin and eosin staining results displayed compactly arranged fibres without intercellular space in cardiomyocytes of sham rats (Fig. 2G). In contrast, disordered myocardial fibres as well as hypertrophic and oedematous cardiomyocytes were observed in the Dox-treated rats (Fig. 2H), which was significantly reversed by BDNF (Fig. 2I). Thus, these findings together displayed that BDNF mitigated Dox-induced cardiac injury in rat ventricular myocytes.

Fig. 3 Cardiac apoptosis and interstitial fibrosis of left ventricles in Dox and BDNF-treated rats. (A-F) TUNEL staining, the images at magnification 200× (scale bar: 50 μm) and 400× (scale bar: 20 μm). (G) Ratio of TUNEL-positive cells (stained in brown) per field. (H-J) Representative Masson trichrome staining images from left ventricles of sham, Dox and BDNF-treated rats. The images were magnified 400×, scale bar: 50 μm. (K) Collagen volume fraction was calculated as the ratio of collagen area to total area. **P < 0.01 versus sham; ##P < 0.01 versus Dox, n = 5 each group.

© 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Effects of BDNF on cardiac apoptosis and fibrosis in Dox-treated rats

We further detected cardiomyocyte apoptosis and interstitial fibrosis in Dox and BDNF-treated rats. As shown in Figure 3A–F, TUNEL assay was used to detect the effect of BDNF on cardiac apoptosis in Dox-treated rat left ventricles at different magnifications. TUNEL-positive cells in left ventricles were significantly higher in the Dox-treated rats than sham rats, which was markedly reduced by BDNF (Fig. 3G). In addition, the cardiomyocytes of sham rats appeared grossly normal under light microscopy. However, obvious interstitial fibrosis was examined in Dox-treated rats. Bundles of myofibres were packed less tightly and were separated by thick layers of fibrous tissue in Dox-treated rats, which was slightly reversed by BDNF (Fig. 3H–J). Statistically, CVF was significantly elevated in Dox-treated rats compared to sham rats but did not significantly change by BDNF (Fig. 3K). Consistently, the effects of Dox and BDNF on cardiac apoptosis and fibrosis in right ventricles were similar to left ventricles (Fig. S1).

Effects of BDNF on oxidative stress and cardiac function in Dox-treated rats

It is well known that SOD, MDA and reduced GSH are good indicators of oxidative stress. Therefore, these markers are examined to assess the effects of BDNF on oxidative stress in our study. It was found that BDNF significantly restored antioxidant markers (SOD activity and GSH content) and decreased MDA level in Dox-treated left and right ventricles (Fig. S1).

Fig. 4 Effect of BDNF on oxidative stress and cardiac function of Dox-treated rats by echocardiography. (A and D) Superoxide dismutase (SOD) activity, (B and E) malondialdehyde (MDA) level and (C and F) reduced glutathione (GSH) content in left and right rat ventricles. (G) Representative images of cardiac function. (H) Ejection fraction (EF). (I) Fractional shortening (FS). (J) LV end systolic volume (LVESV). (K) LV end diastolic volume (LVEDV). *P < 0.05 versus sham, #P < 0.05 versus Dox, n = 5 each group.
ventricles (Fig. 4A–F). We further validated the salutary role of BDNF in protection of Dox-induced cardiac dysfunction. Echocardiographic data indicated that BDNF significantly ameliorated cardiac function in Dox-treated rats (Fig. 4G). In detail, BDNF markedly increased LVEF and FS (Fig. 4H and I), as well as decreased LVESV and LVEDV (Fig. 4J and K). Therefore, the above findings strongly supported that BDNF protected against Dox-induced oxidative stress and cardiac dysfunction.

Effects of BDNF on protein expression of Akt signals in Dox-treated rat ventricles

We then examined the role of Akt signals in the anti-apoptotic effect of BDNF against Dox-induced cardiac injury in both left and right ventricles. It was found that protein level of p-Akt was significantly repressed by Dox, which was recovered by BDNF (Fig. 5A) in left rat ventricles. Meanwhile, no significant change in t-Akt was observed among these groups (Fig. 5A). We further detected protein expression of mTOR and Bad, the downstream signal of PI3K/Akt pathway, and found that p-mTOR and p-Bad were inhibited by Dox and was restored by BDNF. In addition, mTOR and Bad protein levels did not change in those three groups (Fig. 5B and C). Consistently, similar results were found in right ventricles (Fig. 5D–F). So, these data supported that Akt regulated mTOR and Bad signals were involved in the protective effect of BDNF against Dox-induced cardiotoxicity.

Effects of BDNF on protein expression of p38 MAPK and ERK in Dox-treated rat ventricles

Mitogen-activated protein kinase family members including p38 MAPK and ERK were also examined. We found that protein levels of p-p38 and p-ERK as well as ratios of p-p38/p38 and p-ERK/ERK were increased in Dox rats, however, did not significantly change after BDNF treatment (Fig. 6A and B). Similarly, expression of p38 MAPK and ERK in right ventricles are consistent with findings in left ventricles (Fig. 6C and D).

![Protein expression of Akt signalling in Dox and BDNF-treated rats.](image)

- **A** and **D**: Representative western blot bands and statistical results of phosphorylated Akt (p-Akt) and total Akt (t-Akt) of left and right ventricles with GAPDH as internal control.
- **B** and **E**: Representative western blot bands and statistical results of phosphorylated mammalian target of rapamycin (p-mTOR) and mTOR of left and right ventricles.
- **C** and **F**: Representative western blot bands and statistical results of phosphorylated Bad (p-Bad) and Bad of left and right ventricles. *P < 0.05 versus sham, #P < 0.05 versus Dox, n = 5 each group.

© 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Effects of BDNF on cell viability of Dox-treated H9c2 cells

Then, we aimed to validate the effect and mechanisms of BDNF on the cardiotoxicity of Dox in vitro. First, we examined the dose–response of Dox in H9c2 cells. As shown in Figure 7A, the cell viability was markedly reduced by Dox at 1 and 3 μM for 24 hrs, whereas not significantly changed by 0.3 μM Dox. Then, we tested the various time-points and found that Dox (1 μM) treatment for 24 and 48 hrs markedly reduced the cell viability, however, 6 hrs treatment did not significantly reduced the cell viability (Fig. 7B). Accordingly, 1 μM Dox treatment for 24 hrs were selected for subsequent experiments. Furthermore, we detected the effect of BDNF on cell viability treated with Dox. We found that BDNF (400 ng/ml) significantly reversed cell viability induced by Dox (Fig. 7C). Therefore, BDNF (400 ng/ml) was determined for the following studies.

Effects of BDNF on apoptosis and DNA damage in Dox-treated H9c2 cells

TUNEL assay and flow cytometry were employed to confirm the anti-apoptotic effect of BDNF in Dox-treated H9c2 cells. It was suggested that TUNEL-positive cells dramatically increased in Dox group, which was reversed by BDNF (Fig. 7D and E). Phosphorylated γH2AX, a sensitive marker of double-stranded DNA break, was employed to
assess whether BDNF reduced DNA damage in Dox-treated H9c2 cells (Fig. 7F). Fluorescence intensity of \( \gamma H2AX \) was higher in Dox group than untreated cells, which was limited by BDNF (Fig. 7G). Furthermore, as shown in Figure 8A, the apoptotic rate was increased by Dox, which was attenuated by BDNF (Fig. 8B). Taken together, these findings supported that BDNF protected against Dox-induced apoptosis in H9c2 cells.

**TrkB-Fc and Akti abolished the protective role of BDNF in Dox-treated H9c2 cells**

We further confirmed the impact of BDNF on protein expression of Akt in H9c2, and found that BDNF treatment significantly increased p-Akt level without affecting t-Akt level (Fig. 8C and D), which is agreement with previous in vivo results. Then, BDNF blocker TrkB-Fc and Akti were employed to validate the pivotal role of BDNF/TrkB/Akt cascade in beneficial effect of BDNF. The cell viability in BDNF-treated cells was reversed by BDNF scavenger TrkB-Fc or Akti (Fig. 8E). It was also found that the anti-apoptotic effect of BDNF against Dox was significantly restored by TrkB-Fc or Akti (Fig. 8F and G). Collectively, our findings suggest that Akt signal is indispensible for the cardioprotective effect of BDNF against Dox-induced cardiotoxicity.

**Discussion**

This study mainly found that (i) cardiac BDNF expression was down-regulated in Dox-treated rat; (ii) exogenous BDNF inhibited Dox-induced cardiac dysfunction including oxidative stress, DNA damage and cardiomyocyte apoptosis by activating Akt signalling and preserving phosphorylation of mTOR and Bad; (iii) BDNF did not affect p38 MAPK and ERK in Dox-treated rat heart.

In our previous study, it was found that protein expression of BDNF was increased in response to acute ischaemia for 1 or 6 hrs [19]. On the contrary, other study reported that chronic myocardial ischaemia (range from 1 to 14 days) significantly decreased protein level of BDNF with time-dependent manner [15]. Besides, plasma BDNF level was elevated in acute myocardial infarction patients [19] while reduced in heart failure patients [31, 32]. On the basis of these findings, we speculated that increment of BDNF expression in acute injury was a compensatory mechanism while reduction expression
after sustained injury was the outcome of decompensation. In agreement with the above findings, we found that protein level of BDNF in the myocardium of Dox-treated rats was markedly decreased. Exogenous BDNF not only reversed cardiac BDNF expression but also improved Dox-induced cardiac dysfunction. Accordingly, BDNF deficiency is probably the consequence of Dox-induced cardiotoxicity, which was restored after BDNF treatment.

It is well known that TrkB is the high-affinity receptor of BDNF, which is indispensable for functional role of BDNF in both neurons [33] and heart [16, 17]. Our previous study also confirmed the crucial role of BDNF/TrkB pathway in the heart [19]. In this study, we observed the protective effect of BDNF against Dox-induced cardiomyocyte apoptosis was recovered by TrkB-Fc. In addition, TrkB could induce PI3K activity and leads to Akt activation by phosphorylating Akt at ser473 [34]. We demonstrated the BDNF/TrkB/Akt axis in the protection of Dox-induced cardiac injury. Once Akt is activated, the phosphorylation of downstream key molecules mTOR and Bad are up-regulated and regulates many important cellular activities including proliferation, growth, survival and angiogenesis. PI3K/Akt pathway was well recognized to promote survival by downregulating pro-apoptotic factors and up-regulating anti-apoptotic factors. Through phosphorylation, PI3K/Akt inhibits the activity of proapoptotic members while activating anti-apoptotic members [35]. On the other hand, MAPK family members p38 MAPK and ERK have also been demonstrated participated in Dox-induced cardiac dysfunction [26]. In our present study, both p-p38 MAPK and p-ERK were activated by Dox, however, neither of them was affected by BDNF. So, p38 MAPK and ERK were not involved in the protective role of BDNF against Dox-induced injury.

Consistently, it has been previously described with effects of BDNF against Dox-induced apoptosis in cancer cells [36]. Middlemas et al. reported the beneficial role of BDNF against cytotoxic agents...
including cisplatin, Dox and topotecan [20]. They found that BDNF protected cell against DNA damaging caused by these agents. Moreover, they also speculated that BDNF regulate a common signalling pathway which is required for cell death [20]. Similarly, Ho et al. revealed that BDNF/TrkB signalling pathway has a beneficial impact when exposed to DNA-damaging reagents in neuroblastomas. Moreover, they also found that activation of PI3K/Akt survival pathway may contribute to the increased Dox resistance in TrkB-expressing neuroblastomas [21]. Lately, another study reported that BDNF has potent cytoprotective effects against Dox-induced injury in pancreatic β cells [37]. These findings suggest that the protective effect of BDNF may exist in different types of cells.

PI3K/Akt pathway phosphorylates many intracellular substrates [38]. It has been revealed that BDNF exerted its pro-survival effects by binding TrkB and activating downstream signalling pathways. In particular, TrkB-induced PI3K activity lead to Akt activation and thereby phosphorylated downstream pro-apoptotic targets, including Forkhead and Bad2 [39, 40]. Moreover, up-regulation of BDNF activated Akt and promotes hippocampal neuronal proliferation in mice by regulating Bcl-2 and caspase-3 [41]. Combined ampakine and local delivery of BDNF improved post-stroke functional recovery in aged mice by activating Akt/CREB signalling [42]. Here, we validate that phosphorylation of mTOR and Bad are preserved by BDNF in Dox-induced cardiotoxicity. Of course, other signals modulated by BDNF against Dox-induced cardiac injury could not be excluded, although p38 and ERK were determined. But the present findings strongly suggest that Akt signals are central in the protection of BDNF against Dox-induced cardiac injury. On the other hand, although BDNF has promising effect on cardiomyocyte injury, it should be noted that Dox-induced interstitial fibrosis was not significantly ameliorated by BDNF. Thus, whether BDNF reverses cardiac remodeling in several periods of Dox treatment is interesting to study in the following work.

In summary, the findings of this study highlight potential implications of BDNF against Dox-induced cardiac dysfunction, which may enhance our understanding of therapeutic role of neurotrophic factors against chemotherapeutic agents induced cardiotoxicity to facilitate their safe use in cancer treatment.

Acknowledgements

This study was supported by Major Program of National Natural Science Foundation of China (81230081), Natural Science Foundation of China (81300080, 81200077 and 81470462), Natural Science Foundation of Heilongjiang Province (QC2013C087). P.Z.H., Z.M.D., J.Z. and Y.L. designed the study; P.Z.H., J.Z., L.S., M.H.L. and Y.H. performed the research; P.Z.H. and J.Z. analysed the data; P.Z.H., Z.M.D., J.Z. and Y.L. wrote the paper.

Conflict of interest

The authors declare that they have no conflicts of interest.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Figure S1 Cardiac apoptosis and interstitial fibrosis of right ventricles in Dox and BDNF-treated rats.

References

1. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997; 54: 1–7.
2. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56: 185–229.
3. Shi Y, Moon M, Dawood S, et al. Mechanisms and management of doxorubicin cardiotoxicity. Herz. 2011; 36: 296–305.
4. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18: 1639–42.
5. Veipongpa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014; 64: 938–45.
6. Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012; 52: 1213–25.
7. Hiona A, Lee AS, Nagendran J, et al. Pre-treatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011; 142: 396–403.e3.
8. Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010; 85: 894–9.
9. Tashkori Behesti A, Mostafavi Toroghi H, Hosseini G, et al. Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology. 2016; 134: 47–53.
10. Zhang C, Feng Y, Qu S, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res. 2011; 90: 538–45.
11. Gu J, Hu W, Zhang DD. Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity. J Cell Mol Med. 2015; 19: 2324–8.
12. Zhang Y, Liang X, Liao S, et al. Potent paracrine effects of human induced pluripotent stem cell-derived mesenchymal stem cells attenuate doxorubicin-induced cardiomyopathy. Sci Rep. 2015; 5: 11235.
13. Tong Z, Jiang B, Wu Y, et al. MiR-21 protected cardiomyocytes against doxorubicin-induced apoptosis by targeting BTG2. Int J Mol Sci. 2015; 16: 14511–25.
14. Li Y, Jia YC, Cui K, et al. Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. Nature. 2005; 434: 894–8.
15. Okada S, Yokoyama M, Toco H, et al. Brain-derived neurotrophic factor protects against cardiac dysfunction after myocardial infarction via a central nervous system.
mediated pathway. *Arterioscler Thromb Vasc Biol* 2012; 32: 1902–9.

16. Feng N, Huke S, Zhu G, et al. Constitutive BDNF/TrkB signaling is required for normal cardiac contraction and relaxation. *Proc Natl Acad Sci USA* 2015; 112: 1880–5.

17. Fulgenzi G, Tomassoni-Ardori F, Babini L, et al. BDNF modulates heart contraction force and long-term homeostasis through truncated TrkB-T1 receptor activation. *J Cell Biol* 2015; 210: 1003–12.

18. Kermani P, Rafii D, Jin DK, et al. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. *J Clin Invest* 2005; 115: 653–63.

19. Hang P, Zhao J, Cai B, et al. Brain-derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents. *J Neurooncol*. 1999; 45: 27–36.

20. Middlemas DS, Kiwl BK, Moody NM. Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents. *J Neurooncol*. 1999; 45: 27–36.

21. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. *Cancer Res* 2002; 62: 6462–6.

22. Ceci M, Ross J Jr, Condorelli G. Molecular determinants of the physiological adaptation to stress in the cardiomyocyte: a focus on AKT. *J Mol Cell Cardiol* 2004; 37: 905–12.

23. Muslin AJ. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. *Clin Sci (Lond)*. 2008; 115: 203–18.

24. Singla DK. Akt-mTOR pathway inhibits apoptosis and fibrosis in doxorubicin-induced cardiotoxicity following embryonic stem cell transplantation. *Cell Transplant*. 2015; 24: 1031–42.

25. Fan GC, Zhou X, Wang X, et al. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. *Circ Res* 2008; 103: 1270–9.

26. Wang X, Wang XL, Chen HL, et al. Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. *Biochem Pharmacol.* 2014; 88: 34–50.

27. Ramos-Cejudo J, Gutierrez-Fernandez M, Otero-Ortega L, et al. Brain-derived neurotrophic factor administration mediated oligodendrocyte differentiation and myelin formation in subcortical ischemic stroke. *Stroke*. 2015; 46: 221–8.

28. Xing Y, Yang D, Lu J, et al. Insulin prevents bone morphogenetic protein-4 induced cardiomyocyte apoptosis through activating Akt. *Biochem Biophys Res Commun.* 2015; 456: 605–9.

29. Lazzarini E, Balbi C, Attieri P, et al. The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity. *Sci Rep*. 2016; 6: 29994.

30. Yu X, Li T, Liu X, et al. Modulation of pulmonary vascular remodeling in hypoxia: role of 15-LOX-2/15-HETE-MAPKs pathway. *Cell Physiol Biochem*. 2015; 35: 2079–97.

31. Takashio S, Sugiymaya S, Yamamuro M, et al. Significance of low plasma levels of brain-derived neurotrophic factor in patients with heart failure. *Am J Cardiol*. 2015; 116: 249–54.

32. Fukushima A, Kinugawa S, Homma T, et al. Serum brain-derived neurotrophic factor level predicts adverse clinical outcomes in patients with heart failure. *J Card Fail*. 2015; 21: 300–6.

33. Van Kanegan MJ, He DN, Dunn DE, et al. BDNF mediates neuroprotection against oxygen-glucose deprivation by the cardiac glycoside oleandrin. *J Neurosci*. 2014; 34: 963–8.

34. Nakano M, Osada K, Misonou A, et al. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt in PC12 cells. *Life Sci*. 2010; 86: 309–14.

35. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. *Curr Cancer Drug Targets*. 2009; 9: 237–49.

36. Jabon J, Kim CJ, Kaplan DR, et al. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotheraphy-induced apoptosis via phosphatidylinositol 3-kinase pathway. *Cancer Res*. 2002; 62: 6756–63.

37. Bathina S, Srinivas N, Das UN. BDNF protects pancreatic β cells (RIN5F) against cytotoxic action of alloxan, streptozotocin, doxorubicin and benzo[a]pyrene in vitro. *Metabolism*. 2016; 65: 667–84.

38. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell*. 2007; 129: 1261–74.

39. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. *Curr Opin Neurobiol*. 2001; 11: 297–305.

40. Kitamura Y, Koide M, Akakabe Y, et al. Manipulation of cardiac phosphatidylinositol 3-kinase (PI3K)/Akt signaling by apoptosis regulator through modulating IAP expression (ARIA) regulates cardiomyocyte death during doxorubicin-induced cardiomyopathy. *J Biol Chem*. 2014; 289: 2788–800.

41. Luo L, Liu XL, Li J, et al. Macranthol promotes hippocampal neuronal proliferation in mice via BDNF-TrkB/P13K/Akt signaling pathway. *Eur J Pharmacol*. 2015; 762: 357–63.

42. Clarkson AN, Parker K, Nilsson M, et al. Combined ampakine and BDNF treatments enhance poststroke functional recovery in aged mice via AKT-CREB signaling. *J Cereb Blood Flow Metab*. 2015; 35: 1272–9.